Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy

This publication has 29 references indexed in Scilit:

• New Strategies in the Treatment of Multiple Myeloma
  Clinical Cancer Research, 2013
• Multiple Myeloma
  New England Journal of Medicine, 2011
• Treatment Options for Relapsed and Refractory Multiple Myeloma
  Clinical Cancer Research, 2011
• Syndecan-1: a dynamic regulator of the myeloma microenvironment
  Clinical & Experimental Metastasis, 2007
• Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
  Journal of Nuclear Medicine, 2007
• Multiple Myeloma
  New England Journal of Medicine, 2004
• Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma
  Cancer, 2002
• A murine model of human myeloma bone disease
  Bone, 1997
• A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1
  British Journal of Haematology, 1996
• Radiopharmaceutical Therapy of 5T33 Murine Myeloma by Sequential Treatment With Samarium-153 Ethylenediaminetetramethylene Phosphonate, Melphalan, and Bone Marrow Transplantation
  JNCI: Journal of the National Cancer Institute, 1993